Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer

International Journal of Cancer

Volumn 79, Issue 2, 1998, Pages 121-126

  Toffoli, Giuseppe ^a   Russo, Antonio ^a   Gallo, Angelo ^a   Cernicoi, Claudia ^a   Miotti, Silvia ^b   Sorio, Roberto ^a   Tumolo, Salvatore ^a   Boiocchi, Mauro ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; FOLATE BINDING PROTEIN; PLATINUM;

ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOFLUOROMETRY; FLOW CYTOMETRY; HUMAN; MULTIVARIATE ANALYSIS; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 0031944910     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980417)79:2<121::AID-IJC4>3.0.CO;2-V     Document Type: Article

References (34)

1. AL-AZRAQI, A., CHAPMAN, C., CHALLEN, C., SIGALAS, J., ASWAAD, S., SINHA, D., CALVERT, A.H. and LUNEC, J., p53 alterations in ovarian cancer as a determinant of response to carboplatin. Brit, J. Cancer, 69 (Suppl. 21), 7 (1994).
2. ANTONY, A.C., The biological chemistry: of folate receptors. Blood, 79, 2807-2820 (1992).
3. BASU, A. and CLINE, J.S., Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Int. J. Cancer, 63, 597-603 (1995).
4. BOTTERO, F., TOMASSETTI, A., CANEVARI, S., MIOTTI, S., MENARD, S. and COLNAGHI, M.I., Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res., 53, 5791-5796 (1993).
5. CANNISTRA, S.A., Cancer of the ovary. N. Engl. J. Med., 329, 151 (1993).
6. CAZIN, J.L., GOSSELIN, P., CAPPELAERE, P., ROBERT, J. and DEMAILLE, A., Drug resistance in oncology: from concepts to applications. J. Cancer Res. clin. Oncol., 119, 76-86 (1992).
7. CHEVILLARD, S., POUILLART, P., BELDJORD, C., ASSELAIN, B., BEUZEBOC, P., MAGDELENAT, H. and VIELH, P., Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer, 77, 292-300 (1996).
8. CHUNG, K.N., SAIKAWA, Y., PAIK, T.H., DIXON, K.H., MULLIGAN, T., COWAN, K.H. and ELWOOD, P.C., Stable transfectants of human MCF-7 breast caneer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates. J. clin. Invest., 91, 1289-1294 (1993).
9. CONEY, L.R., TOMASSETTI, A., CARAYANNOPOULOS, L., FRASCA, V., KAMEN, B.A., COLNAGHI, M.I. and ZURAWSKI, V.R., Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res., 51, 6125-6132 (1991).
10. COX, D.R., Regression models and life tables. J. roy. Stat. Soc. B., 34, 187-220 (1972).
11. DEMBO, A.J. and BUSH, R.S., Choice of postoperative therapy based on prognostic factors. Int. J. Rad. Oncol. Biol. Phys., 8, 893-897 (1982).
12. FISHER, D.E., Apoptosis in cancer therapy: crossing the threshold. Cell, 78, 539-542 (1994).
13. FRIEDLANDER, M.L. and DEMBO, A.J., Prognostic factors in ovarian cancer. Semin. Oncol., 18, 205-212 (1991).
14. INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS, Changes in definition of clinical staging for carcinoma of the cervix and ovary. Amer. J. Obstet. Gynecol., 56, 263-264 (1987).
15. KAPLAN, E.L. and MEIER, P., Nonparametric estimation for incomplete observations. J. Amer. stat. Assoc., 53, 457-481 (1958).
16. KLEMI, P.J., PYLKKANEN, L., KIILHOLMA, P., KURVINEN, K. and JOENSUU, H., p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer, 76, 1201-1208 (1995).
17. MANTOVANI, L.T., MIOTTI, S., MÉNARD, S., CANEVARI, S., RASPAGLIESI, F., BOTTINI, C., BOTTERO, F. and COLNAGHI, M.I., Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Europ. J. Cancer, 30A, 363-369 (1994).
18. MIOTTI, S., CANEVARI, S., MÉNARD, S., MEZZANZANICA, D., PORRO, G., PUPA, S.M., REGAZZONI, M., TAGLIABUE, E. and COLNAGHI, M.I., Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer, 39, 297-303 (1987).
19. OTTONE. F., MIOTTI, S., BOTTINI, C., BAGNOLI, M., PEREGO, P., COLNAGHI, M.I. and MÉNARD, S., Relationship between folate binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. Brit. J. Cancer, 76, 77-82 (1997).
20. PETO, J. and EASTON, D., Randomized cancer trials - past failures, current progress and future prospects? Cancer Surv., 8, 511-533 (1990).
21. RIGHETTI, S.C. and 13 others, A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res., 56, 689-693 (1996).
22. ROSS, J.F., CHAUDHURI, P.K. and RATNAM, M., Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer, 73, 2432-2443 (1994).
23. RUSTIN, G.J., NELSTROP, A.E., MCCLEAN, P., BRADY, M.F., MCGUIRE, W.P., HOSKINS, W.J., MITCHELL, H. and LAMBERT, H.E., Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. clin. Oncol., 14, 1545-1551 (1996).
24. SARGIACOMO, M., SUDOL, M., TANG, Z. and LISANTI, M.P., Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J. Cell Biol., 122, 789-807 (1993).
25. SEN, S., ERBA, E., D'INCALCI, M., BOTTERO, F., CANEVARI, S. and TOMASSETTI, A., Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro. Brit. J. Cancer, 73, 525-530 (1996).
26. SEROV, S.F., and SCULLY R.E., Histological typing of ovarian tumors. In: International histological classification of tumors, World Health Organization, Geneva (1973).
27. SHEN, F., ROSS, J.F., WANG, X. and RATNAM, M., Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry, 33, 1209-1215 (1994).
28. STEFANOVA, I., HOREJSI, V., ANSOTEGUI, I.J., KNAPP, W. and STOCKINGER, H., GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science, 254, 1016-1019 (1991).
29. SUN, X., MURPHY, B.R., LI, Q., GULLAPALLI, S., MACKINS, J., JAYARAM, H., SRIVASTAVA, A. and ANTONY, A., Transduction of folate receptor cDNA into cervical carcinoma cells using recombinant adeno-associated virions delays cell proliferation in vitro and in vivo. J. clin. Invest., 96, 1535-1547 (1995).
30. SOBIN, L.H. and WITTEKIND, C. (EDS.), TNM classification of malignant tumors. Wiley-Liss, New York, (1997).
31. TOFFOLI, G., CERNIGOI, C., RUSSO, A., GALLO, A., BAGNOLI, M. and BOIOCCHI, M., Overexpression of folate binding protein in ovarian cancer. Int. J. Cancer (Pred. Oncol.), 74, 193-198 (1997).
32. VAN DER ZEE, A.G., HOLLEMA, H., SUURMEIJER, A.J., KRANS, M., SLUITER, W.J., WILLEMSE, P.H., AALDERS, J.G. and DE VRIES, E.G., Value of p-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. clin. Oncol., 13, 70-78 (1996).
33. VAN HOUWELINGEN, J.C., TEN BOKKEL, HUININK, W.W., VAN DER BURG, M.E., VAN OOSTEROM, A.T. and NEIJT, J.P., Predictability of the survival of patients with advanced ovarian cancer. J. clin. Oncol., 7, 769-773 (1989).
34. VERMORKEN, J.B. and HOEKMAN, K., Chemotherapy for gynecologic malignancies. Curr. Opin. Oncol., 7, 457-465 (1995).